A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration

Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: Results from a prospective multicenter study

(2013) Andreas A. Argyriou et al.   CANCER

Chemotherapy-Induced Neuropathy and Its Association With Quality of Life Among 2- to 11-Year Colorectal Cancer Survivors: Results From the Population-Based PROFILES Registry

(2013) Floortje Mols et al.   JOURNAL OF CLINICAL ONCOLOGY

Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients

(2013) R. Velasco et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

A descriptive study of persistent oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer

(2013) Sina Vatandoust et al.   SUPPORTIVE CARE IN CANCER

Oxaliplatin-induced peripheral neuropathy’s effects on health-related quality of life of colorectal cancer survivors

(2013) Cindy Tofthagen et al.   SUPPORTIVE CARE IN CANCER

Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients

(2012) A. A. Argyriou et al.   ANNALS OF ONCOLOGY

Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: Results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01

(2012) Kelley M. Kidwell et al.   CANCER

Gain-of-function Nav1.8 mutations in painful neuropathy

(2012) C. G. Faber et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Gain of function NaV1.7 mutations in idiopathic small fiber neuropathy

(2011) Catharina G. Faber et al.   ANNALS OF NEUROLOGY

Literature Review and Practical Aspects on the Management of Oxaliplatin-Associated Toxicity

(2011) Paulo M. Hoff et al.   Clinical Colorectal Cancer

Oxaliplatin As Adjuvant Therapy for Colon Cancer: Updated Results of NSABP C-07 Trial, Including Survival and Subset Analyses

(2011) Greg Yothers et al.   JOURNAL OF CLINICAL ONCOLOGY

Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer

(2011) Daniel G. Haller et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-Term Neuropathy After Oxaliplatin Treatment: Challenging the Dictum of Reversibility

(2011) S. B. Park et al.   ONCOLOGIST

Dose Effects of Oxaliplatin on Persistent and Transient Na+ Conductances and the Development of Neurotoxicity

(2011) Susanna B. Park et al.   PLoS One

Capecitabine combined with oxaliplatin (CapOx) in clinical practice: how significant is peripheral neuropathy?

(2010) D. J. Storey et al.   ANNALS OF ONCOLOGY

Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer

(2010) Michel Ducreux et al.   INTERNATIONAL JOURNAL OF CANCER

Persistent neuropathy after treatment with cisplatin and oxaliplatin

(2009) Elke E. M. Brouwers et al.   ACTA ONCOLOGICA

Safety and tolerability of FOLFOX4 in the adjuvant treatment of colon cancer in Asian patients: The MASCOT study

(2009) Po-Huang LEE et al.   Asia-Pacific Journal of Clinical Oncology

Initial Safety Report of NSABP C-08: A Randomized Phase III Study of Modified FOLFOX6 With or Without Bevacizumab for the Adjuvant Treatment of Patients With Stage II or III Colon Cancer

(2009) Carmen J. Allegra et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial

(2009) Thierry André et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and Efficacy of Modified FOLFOX6 for Treatment of Metastatic or Locally Advanced Colorectal Cancer

(2008) Shigemi Matsumoto et al.   CHEMOTHERAPY